Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer

Keskinkılıç M., Canaslan K., Semiz H. S., Yavuzşen T.

Forbes tıp dergisi (Online), cilt.6, sa.2, ss.180-187, 2025 (Hakemli Dergi)

Özet

ABSTRACT

Objective

The aim of this study is to reveal the relationship and correlation between the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) risk models used to determine first-line treatment in metastatic mRCC and, less commonly, the Cleveland Clinic Foundation (CCF) prognostic risk model.

Methods

The IMDC, MSKCC and CCF scores of mRCC patients who received immunotherapy (IO) and molecular targeted therapy were calculated retrospectively at the time of diagnosis.According to the score results, the patients were grouped as favorable,intermediate and poor risk.According to these risk groups,the median progression-free survival (mPFS) and median overall survival (mOS) of the patients were calculated and the correlation with each other was considered significant using appropriate statistical analyses, and p<0.05 was considered significant.

Results

The median follow-up time of 189 patients in the study was 45.5 months, mPFS 23.6 months [95% confidence interval (CI): 18.6-28.5 months] and mOS 34.6 months (95% CI: 23.3-45.9 months).The distribution of patients according to risk groups was similar in all three prognostic risk models. In the poor-risk group, both mPFS and mOS were statistically significantly shorter according to all three risk models (mPFS, IMDC: 14.2 months, MSKCC: 15.6 months, CCF: 17.1 months; mOS, IMDC: 17.6 months, MSKCC: 17.7 months, CCF: 22.4 months, p<0.001). A statistically significant positive correlation was observed between CCF, MSKCC and IMDC (r=0.656 vs. r=0.690, p<0.001). A stronger and statistically significant positive correlation was observed between MSKCC and IMDC (r=793, p<0.001).

Conclusion

Our study is the first study in the literature that we know of comparing the IMDC, MSKCC and CCF risk models in mRCC receiving IO and targeted therapy and as a result of our study, it was shown that all three risk models were correlated with each other.